You are viewing: China Nuclear Medicine Market analysis
Part of: Nuclear Medicine Market (Global)

The China Nuclear Medicine Market was valued at $587.5 Million in 2025 and projected to reach to $1339.4 Million by 2030, representing a compound annual growth rate of 17.9%. China's nuclear medicine market is positioned for exceptional growth through 2030, supported by government healthcare initiatives and expanding diagnostic infrastructure.

China Nuclear Medicine Market (2025-2030) : Size and Share
logo-mobile
CAGR of
cagr-Chart
USD Million
MARKET SNAPSHOT
Market Size in USD 26.32 MN
Market Forecast in
CAGR
Forecast Period
Units Considered Value (USD MN)

China Nuclear Medicine Market Trends and Insights

  • This represents a compound annual growth rate of 17.9%, significantly outpacing global trends.
  • China's rapid healthcare modernization, increasing prevalence of chronic diseases, and substantial government investment in diagnostic imaging infrastructure are driving this accelerated growth trajectory. The nuclear medicine sector in China is benefiting from rising demand for advanced diagnostic and therapeutic procedures, particularly in oncology and cardiology applications.
  • China's expanding middle class and improved healthcare accessibility are fueling adoption of nuclear medicine technologies across urban and emerging markets.
  • Between 2025 and 2030, China is expected to consolidate its position as a key growth engine within the Asia Pacific nuclear medicine landscape, supported by regulatory reforms and increased clinical adoption of radiopharmaceuticals..

Key Market Statistics

  • CAGR (2025-2030) 17.9% CAGR
  • Market Size, 2025 ~USD 587.5 Million
  • Forecast, 2030 ~USD 1339.4 Million
  • Country China

China Nuclear Medicine Market Overview

Fastest Growing Market Globally :

China's nuclear medicine market grows at 17.9% CAGR, significantly exceeding the global rate of 15.1%, driven by healthcare modernization and rising chronic disease prevalence.

Rapid Market Expansion :

Market valuation is projected to more than double from USD 587.5 million in 2025 to USD 1,339.4 million by 2030, reflecting strong investment in diagnostic imaging infrastructure.

Government-Backed Growth :

Substantial government investment in healthcare modernization and diagnostic imaging facilities accelerates adoption of nuclear medicine technologies across Chinese hospitals and diagnostic centers.

Chronic Disease Burden :

Increasing prevalence of cancer, cardiovascular diseases, and neurological disorders in China's aging population drives demand for advanced nuclear medicine diagnostic and therapeutic solutions.

China Nuclear Medicine Market Dynamics

  • The country's aging demographic profile and rising chronic disease incidence create sustained demand for nuclear imaging and therapeutic applications.
  • Healthcare providers are increasingly adopting PET-CT, SPECT, and radiopharmaceutical therapies to improve diagnostic accuracy and patient outcomes.
  • Investment in medical technology and regulatory improvements will further accelerate market penetration across tier-1 and tier-2 cities. The competitive landscape is intensifying as both domestic and international players establish manufacturing and distribution networks in China.
  • Technological advancements in imaging equipment, coupled with growing awareness among healthcare professionals and patients, will drive market expansion.
  • Government reimbursement policies and healthcare spending increases position China as a critical growth engine for the global nuclear medicine industry through the forecast period..

Related Ecosystem

Pharmaceuticals

Top Technologies
  • Bioreactors
  • Analytical Testing
  • Bioanalytical Testing Services
  • Cell Counters
  • Data Management Services
Top Companies
  • Merck KGaA
  • Thermo Fisher Scientific Inc.
  • SANOFI
  • NOVARTIS
  • Pfizer Inc.

    Key Takeaways

    • China's nuclear medicine market will nearly double from $587.5M (2025) to $1,339.4M (2030), driven by 17.9% CAGR.
    • Government healthcare investments and modernization initiatives position China as the Asia Pacific's fastest-growing nuclear medicine market.
    • Rising chronic disease prevalence and expanding middle-class healthcare demand accelerate radiopharmaceutical adoption across China.
    • Regulatory reforms and clinical infrastructure development in China create sustained growth opportunities through 2030.

    Nuclear Medicine Market Report Scope

    Report Metric Details
    Base Year 2025
    Fastest Growing Segment THERAPEUTIC NUCLEAR MEDICINE (Type)
    Forecast Period 2025–2030
    Growth Rate CAGR of 15.1% from 2025 to 2030
    Largest Segment DIAGNOSTIC NUCLEAR MEDICINE (Type)
    Market Size Base Year (Billions) ~USD 10.4 (2025)
    Revenue Forecast (Billions) ~USD 21.01 (2030)
    Segments Covered Type

    China Nuclear Medicine Market Report Segmentation

    1 segment dimensions are covered across the global market.

    By Type

    • Alpha Emitters
    • Beta Emitters
    • Brachytherapy Isotopes
    • Diagnostic Nuclear Medicine
    • F-18
    • Ga-67
    • I-123
    • I-131
    • Lu-177
    • Other Beta Emitters
    • Other Pet Radiopharmaceuticals
    • Other Spect Radiopharmaceuticals
    • Pet Radiopharmaceuticals
    • Ra-223
    • Rb-82
    • Sm-153
    • Spect Radiopharmaceuticals
    • Tc-99M
    • Therapeutic Nuclear Medicine
    • Tl-201
    • Y-90

    CHINA: NUCLEAR MEDICINE MARKET, BY END USER, 2023–2030

    Segment20232024202520262027202820292030CAGR (%)
    ACADEMIC & RESEARCH INSTITUTES4350.35969.18194.8111129.817.1
    DIAGNOSTIC & IMAGING CENTERS114.6136.6162.8194.1231.3275.6328.1390.119.1
    HOSPITALS252.5297349.5411.4484569.1668.8784.817.6
    OTHER END USERS11.913.916.218.92225.629.834.716.5
    TOTAL422497.8587.5693.4818.2965.11137.71339.417.9

    Target Audience

    • Medical Device Manufacturers : Manufacturers of nuclear imaging equipment and radiopharmaceuticals need China-specific market data to assess expansion opportunities, competitive positioning, and regulatory requirements in this high-growth market.
    • Healthcare Investors & PE Firms : Investment professionals require detailed market sizing, growth projections, and trend analysis for China to evaluate portfolio opportunities and make informed capital allocation decisions in healthcare.
    • Hospital & Diagnostic Center Operators : Healthcare facility managers need market intelligence on technology adoption rates, reimbursement policies, and competitive benchmarks to optimize nuclear medicine service offerings in China.
    • Pharmaceutical & Biotech Companies : Companies developing radiopharmaceuticals and therapeutic nuclear medicine solutions require China market insights to guide R&D investments, commercialization strategies, and partnership development.
    • Healthcare Consultants & Analysts : Consulting firms and research analysts need authoritative China nuclear medicine market data to support client advisory services, market assessments, and strategic recommendations.

    Reasons to Buy this Report

    • Market Size & Growth Validation : Obtain precise valuation data for China's nuclear medicine market with verified 17.9% CAGR, enabling accurate financial forecasting and investment decision-making for the period 2025-2030.
    • Competitive Intelligence : Understand market dynamics, key players, and competitive positioning specific to China's nuclear medicine sector to identify partnership opportunities and market entry strategies.
    • Regulatory & Reimbursement Insights : Access detailed analysis of Chinese government policies, healthcare spending trends, and reimbursement frameworks driving nuclear medicine adoption and market expansion.
    • Segment & Application Analysis : Identify high-growth segments within China's nuclear medicine market, including diagnostic imaging, therapeutic applications, and emerging technologies with the strongest revenue potential.
    • Strategic Planning & Risk Assessment : Leverage comprehensive market data to develop informed go-to-market strategies, assess competitive risks, and allocate resources effectively in China's rapidly expanding healthcare sector.

    Frequently asked questions

    What is the projected size of China's nuclear medicine market by 2030?

    China's nuclear medicine market is projected to reach USD 1,339.4 million by 2030, up from USD 587.5 million in 2025.

    What is the CAGR for China's nuclear medicine market?

    China's nuclear medicine market is expected to grow at a compound annual growth rate of 17.9% between 2025 and 2030.

    What factors are driving growth in China's nuclear medicine market?

    Key drivers include government healthcare modernization investments, rising chronic disease prevalence, expanding middle-class healthcare demand, and increased adoption of advanced diagnostic imaging technologies.

    How does China's nuclear medicine market growth compare to global trends?

    China's 17.9% CAGR significantly outpaces the global nuclear medicine market CAGR of 15.1%, positioning China as a high-growth regional leader.

    Which applications are driving nuclear medicine demand in China?

    Oncology and cardiology applications are primary growth drivers, supported by increasing clinical adoption of radiopharmaceuticals and diagnostic procedures across China's healthcare system.

    RESEARCH METHODOLOGY

    This study involved four major activities in estimating the size of the nuclear medicine market. Exhaustive secondary research was done to collect information on the market, peer market, and parent market. The next step was to validate these findings, assumptions, and sizing with industry experts across value chains through primary research. The bottom-up approach was employed to estimate the overall market size. After that, market breakdown and data triangulation were used to estimate the market size of segments and sub-segments.

    Secondary Research

    The secondary research process involved the widespread use of secondary sources, directories, databases (such as Bloomberg Businessweek, Factiva, and D&B Hoovers), white papers, annual reports, company house documents, investor presentations, and SEC filings of companies. Some non-exclusive secondary sources include the Organisation for Economic Co-operation and Development (OECD), European Association of Nuclear Medicine (EANM), National Institutes of Health (NIH), World Nuclear Association (WNA), International Atomic Energy Agency (IAEA), Nuclear Regulatory Commission (NRC), Society of Nuclear Medicine and Molecular Imaging (SNMMI), Nuclear Energy Agency (NEA), Australian Nuclear Science and Technology Organisation (ANSTO), Annual Reports, SEC Filings, Investor Presentations, Journals, Publications from Government Sources and Professional Associations, Expert Interviews, and MarketsandMarkets Analysis.

    Secondary research was used to identify and collect information useful for the extensive, technical, market-oriented, and commercial study of the clinical decision support system market. It was also used to obtain important information about the key players and market classification and segmentation according to industry trends to the bottom-most level, and key developments related to market and technology perspectives. A database of the key industry leaders was also prepared using secondary research.

    Primary Research

    In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. The primary sources from the supply side include industry experts such as CEOs, vice presidents, marketing and sales directors, technology & innovation directors, and related key executives from various key companies and organizations operating in the clinical decision support system market. The primary sources from the demand side included industry experts, consultants, healthcare providers, hospital administration, and government bodies. Primary research was conducted to validate the market segmentation, identify key players in the market, and gather insights on key industry trends and key market dynamics.

    Breakdown of Primary Interviews

    Nuclear Medicine Market Size, and Share

    Note 1: Others include sales managers, marketing managers, business development managers, product managers, distributors, and suppliers.

    Note 2: Tiers of companies are defined on the basis of their total revenue in 2022; Tier 1: >USD 1 billion, Tier 2: USD 500 million to USD 1 billion, and Tier 3: <USD 500 million.

    To know about the assumptions considered for the study, download the pdf brochure

    Report Metric

    Details

    Siemens Healthineers

    Sr.Sales Manager

    Curium

    General Manager

    Cardinal Health

    Product Sales Specialist

    Market Size Estimation

    Both top-down and bottom-up approaches were used to estimate and validate the total size of the nuclear medicine market. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:

    • The key players in the industry and markets have been identified through extensive secondary research
    • The industry’s supply chain and market size, in terms of value, have been determined through primary and secondary research processes
    • All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources

    Data Triangulation

    After arriving at the overall market size—using the market size estimation processes as explained above—the market was split into several segments and sub-segments. To complete the overall market engineering process and arrive at the exact statistics of each market segment and subsegment, the data triangulation, and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides, in the provider, payer, and other industries.

    Market Definition

    Radiopharmaceuticals are drugs that contain radionuclide-emitting ionizing radiation and are used in nuclear imaging to diagnose and treat diseases. The nuclear medicine market is bifurcated into diagnostic and therapeutic segments. Radiopharmaceuticals in the diagnostics market are categorized as SPECT and PET, while radiopharmaceuticals in the therapeutics market are categorized as beta emitters, alpha emitters, and brachytherapy isotopes.

    Key Stakeholders

    • Senior Management
    • Finance/Procurement Department
    • R&D Department

    Report Objectives

    • To define, describe, and forecast the nuclear medicine market on the basis of type, application, procedure volume,end user, and region
    • To provide detailed information regarding the major factors influencing the market growth (such as drivers, restraints, opportunities, and challenges)
    • To strategically analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall market
    • To analyze the opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
    • To forecast the size of the market segments with respect to four main regions—North America, Europe, the Asia Pacific, and the Rest of the World (RoW)
    • To profile the key players and comprehensively analyze their market shares and core competencies
    • To track and analyze competitive developments such as partnerships, collaborations, agreements, product approval & enhancements, expansions, and acquisitions in the nuclear medicine market

    Available Customizations

    MarketsandMarkets offers the following customizations for this market report:

    • Additional country-level analysis of the nuclear medicine market.
    • Profiling of additional market players (up to 3)

    Get the Full Nuclear Medicine Market Report

    Full forecast, segment splits, and company analysis for all Nuclear Medicine Market.

    Need a Tailored Report?

    Customize this report to your needs

    Get 10% FREE Customization

    Customize This Report
    Fact checked
    DMCA.com Protection Status